Werewolf Therapeutics (NASDAQ:HOWL) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Posted by Eileen French on Nov 10th, 2024

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03, reports. Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock opened at $2.30 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.13 and a quick ratio of 12.13. The firm has a 50-day moving average of $2.27 and a 200-day moving average of $3.02. Werewolf Therapeutics has a one year low of $1.66 and a one year high of $8.19. The company has a market cap of $100.51 million, a P/E ratio of -1.67 and a beta of 0.41.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Werewolf Therapeutics during the 3rd quarter worth approximately $29,000. Point72 DIFC Ltd purchased a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $34,000. Rhumbline Advisers bought a new stake in Werewolf Therapeutics during the second quarter worth $79,000. American Century Companies Inc. boosted its position in Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after purchasing an additional 12,656 shares during the last quarter. Finally, Murchinson Ltd. bought a new position in Werewolf Therapeutics in the 2nd quarter valued at $152,000. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.